This Year In Medicine

A group of investigators, researchers and policymakers discuss the issues, innovations and aspirations that may define 2023 advances.

Why has this season brought an unprecedented number of severe RSV infections, and why is vaccine development taking so long?

Allergic contact dermatitis burden many people, but it is important for patients to know why and how they may limit their risk.

This novel concept can benefit patients and clinicians alike by appropriately applying new technologies to identify bacteria more efficiently and decrease the time to optimal therapy.

The past year has provided great steps forward in sleep science, and coupled with the lingering difficulties in care and the COVID-19 pandemic’s effects, the field is coming to a head to make sleep health a public health priority.

The FDA's plans to expedite and expand regulatory pathways has resulted in a novel drug development boom since 2017. The commissioner discusses the details of their strategy.

As physician demands continue to climb in the high-demand specialty, patient-reported outcomes have emerged as a viable tool in assessment and care.

With a great deal of marginalized patients navigating burdensome, chronic, heterogenetic disease today, rheumatologists are becoming more invested in what the individual needs and wants from care.

Almost 4 years since the beginning of the pandemic, continuous research efforts have begun to paint a better picture of the impact the virus has on the brain and the central nervous system.

With several newly approved therapies hitting the market and an overflowing pipeline, the FDA has stepped in to help keep the burgeoning world of biotech on track.

Reflections on a century's worth of developments toward a major breakthrough in T1D this year.

This year saw 4 new FDA approvals for the chronic condition. But dermatologists are still not satisfied.

In 2021, the USPSTF changed guidance on colorectal cancer screenings, reducing the recommended age of a colonoscopy from 50 to 45 years.

As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased. In recent years, GFAP has emerged as a valuable candidate to add to the existing panel.

After decades of unmet needs in the progressive form of vision loss, the complement inhibitor drug class is nearing the market for affected patients.

A pediatric emergency medicine physician discusses the epidemic factors that still perturb experts, and the status of vaccination and treatment strategies.

As we begin our annual health care recap series this month, let's take a look back at the stories our readers liked most.